Abnormal expressions in schizophrenia of ionotropic glutamate receptors (iGluRs) and the proteins that regulate their trafficking have been found to be region and subunit specific in brain, suggesting that abnormal trafficking of iGluRs may contribute toward altered glutamatergic neurotransmission. The post-translational modification N-glycosylation of iGluR subunits can be used as a proxy for their intracellular localization. Receptor complexes assemble in the lumen of the endoplasmic reticulum, where N-glycosylation begins with the addition of N-linked oligomannose glycans, and is subsequently trimmed and replaced by more elaborate glycans while trafficking through the Golgi apparatus. Previously, we found abnormalities in N-glycosylation of the GluR2 AMPA receptor subunit in schizophrenia. Here, we investigated N-glycosylation of N-methyl-D-aspartate and kainate (KA) receptor subunits in the dorsolateral prefrontal cortex from patients with schizophrenia and a comparison group. We used enzymatic deglycosylation with two glycosidases: endoglycosidase H (Endo H), which removes immature high mannose-containing sugars, and peptide-N-glycosidase F (PNGase F), which removes all N-linked sugars. The NR1, NR2A, NR2B, GluR6, and KA2 subunits were all sensitive to treatment with Endo H and PNGase F. The GluR6 KA receptor subunit was significantly more sensitive to Endo H-mediated deglycosylation in schizophrenia, suggesting a larger molecular mass of N-linked high mannose and/or hybrid sugars on GluR6. This finding, taken with our previous work, suggests that a cellular mechanism underlying abnormal glutamate neurotransmission in schizophrenia may involve abnormal trafficking of both AMPA and KA receptors. 
Introduction
Growing evidence implicates glutamate receptor dysfunction in the pathophysiology of schizophrenia, but the underlying mechanism remains unknown. Hypotheses involving glutamate abnormalities in this illness have led to the direct study of glutamate receptors and other proteins associated with glutamate neurotransmission in post-mortem brain in schizophrenia. Numerous studies have found altered expression of glutamate receptor subunits in schizophrenia brain, but changes have been modest and inconsistent [1] . Multiple studies, however, have noted robust alterations in the expression of proteins that regulate trafficking and activity of glutamate receptors [1] [2] [3] [4] [5] [6] [7] . In addition, we have previously found evidence suggestive of disturbances in the trafficking of glutamate receptors in schizophrenia, including the endosomal trafficking of AMPA receptors [5, 8] , as well as the trafficking of AMPA [9] and N-methyl-D-aspartate (NMDA) [10, 11] receptors from the endoplasmic reticulum (ER) to the plasma membrane. These data suggest that glutamate dysfunction in schizophrenia may be associated with the processing and trafficking of glutamate receptors rather than abnormal receptor expression.
Trafficking of glutamate receptors, after their exit from the ER, can be studied by measurement of the extent of N-glycosylation of receptor subunits [9] . We have previously observed a significantly smaller fraction of GluR2 with high mannose sugars in schizophrenia, which may indicate accelerated exit from the ER or increased forward trafficking of GluR2-containing AMPA receptors in this disorder [9] . We have also found that EAAT1 and EAAT2, two of the excitatory amino acid transporters, are less N-glycosylated in schizophrenia, which also suggests the accelerated exit from the ER and abnormal forward trafficking of these transporters in this disorder [12] . It is possible that abnormal N-glycosylation of glutamate receptors and other molecules associated with glutamate neurotransmission could contribute toward the pathophysiology of schizophrenia by altering the forward trafficking of those proteins. Given our previous findings, in this work, we studied N-linked glycosylation of subunits of the NMDA and kainate (KA) receptors in post-mortem brain in schizophrenia. We hypothesized that abnormalities in N-linked glycosylation of ionotropic glutamate receptor (iGluR) subunits are not restricted to AMPA receptors in schizophrenia and may be found for NMDA and/or KA receptor subunits as well.
Materials and methods
Tissue acquisition and sample preparation Dorsolateral prefrontal cortex (DLPFC) samples from patients with schizophrenia [N = 35: age = 74±12 years; post-mortem interval (PMI) = 12.5±6.6 h; tissue pH = 6.4±0.3; 66% men, 34% women] and from a comparison group (N = 31: age = 78±14 years; PMI = 8.1±6.9 h; tissue pH = 6.4±0.2; 39% men, 61% women) were from the Mount Sinai Medical Center brain collection and were used for this study as described previously [9, 13] . Not all patients were available for each separate experiment. Consent was obtained from the next of kin for each patient. Patients were diagnosed with schizophrenia using the DSM-III-R criteria, and each patient had psychotic symptoms before the age of 40 and at least 10 years of hospitalization, with a diagnosis of schizophrenia made by two experienced clinicians. Patients were recruited prospectively and underwent an extensive antemortem clinical assessment. None of the patients had a history of alcoholism, substance abuse, death by suicide, coma for more than 6 h before death, or any neuropathological evidence of neurodegenerative disorders. The participants in this study were matched for sex, tissue pH, PMI, and age as described previously [9, 13] .
Brains were collected at autopsy and cut in the coronal plane into 10 mm slabs. DLPFC was dissected from tissue slabs, snap frozen, pulverized into powder, and stored at -801C until used. Samples were reconstituted and homogenized in ice-cold buffer (5 mM Tris-HCl, pH 7.4, 0.32 M sucrose) with a protease inhibitor tablet (Complete Mini; Roche Diagnostics, Mannheim, Germany) using a Power Gen 125 homogenizer (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and protein concentration was determined using a bicinchoninic acid assay kit (Thermo Fisher Scientific).
Enzymatic deglycosylation
Samples (50 mg total protein per reaction) were incubated at 371C for 16 h with endoglycosidase H (Endo H) or peptide-N-glycosidase F (PNGase F) (New England Biolabs, Ipswich, Massachusetts, USA) according to the manufacturer's protocol. After enzymatic deglycosylation, samples were mixed with 6 Â protein sample buffer (0.25 M Tris-HCl, pH 6.8, 5 mM EDTA, 5 mM ethylene glycol tetra-acetic acid, 50 mM dithiothreitol, 6% SDS, 30% glycerol, and bromophenol blue as the tracking dye), heated at 951C for 10 min, and resolved for 1.5 h at 180 V on 4-12% gradient SDS-polyacrylamide gels (Invitrogen, Carlsbad, California, USA). Proteins were transferred from SDS-polyacrylamide gels to polyvinylidene fluoride using a BioRad semi-dry transblotter (Bio-Rad Laboratories, Hercules, California, USA GluR6 expression-level analysis For total GluR6 expression-level studies, the homogenized DLPFC samples were diluted with ultrapure water (Milli-Q A10; Millipore), mixed with 6 Â protein sample buffer (0.25 M Tris-HCl, pH 6.8, 5 mM EDTA, 5 mM ethylene glycol tetra-acetic acid, 50 mM dithiothreitol, 6% SDS, 30% glycerol, and bromophenol blue as the tracking dye), heated at 951C for 10 min, resolved on SDS-polyacrylamide gels, and transferred to nitrocellulose as above. The membranes were blocked in LiCor blocking buffer and then incubated overnight at 41C in LiCor blocking buffer with 0.1% Tween 20 and with antiGluR6 (C18) goat polyclonal (#7618, 1 : 250; Santa Cruz Biotechnology) or anti-b-tubulin mouse monoclonal (#05-661, 1 : 100 000; Millipore) antibodies. The membranes were washed in PBST and probed with infrareddye-labeled secondary anti-goat or anti-mouse antibodies (1 : 10 000; LiCor Biosciences) for 1 h at room temperature. The membranes were rinsed three times for 15 min with PBST and briefly with deionized water.
Data analysis
The near-infrared fluorescence values for each protein band were determined using a LiCor Odyssey scanner (LiCor Biosciences) and the migration distance for each NMDA or KA receptor subunit was measured using Odyssey V3.0 software (LiCor Biosciences). For analysis of N-glycosylation of NMDA and KA receptor subunits, we quantified two dependent variables: (a) Endo Hsensitive molecular mass shifts for NR1, NR2A, NR2B, GluR6, and KA2 and (b) PNGase F-sensitive molecular mass shifts for NR2A, NR2B, GluR6, and KA2. The distance was measured between deglycosylated protein bands of higher mobility after treatment with Endo H or PNGase F and the same protein in the control reaction in the adjacent lane without Endo H or PNGase F, respectively (Fig. 1) . The migration distance for each receptor subunit was converted into molecular mass shift for each subunit, as described previously [9, 12] . For total GluR6 expression-level studies, the near-infrared fluorescence value for each GluR6 protein band was determined using a LiCor Odyssey scanner and normalized to the values collected for intralane b-tubulin from each patient [9] .
Data were analyzed using the Statistica software package (Statsoft, Tulsa, Oklahoma, USA). All dependent measures were found to be normally distributed. Correlation analyses were carried out to determine associations between the dependent variables and age, PMI, and tissue pH. No correlations were found between these variables and any dependent measures. Data were analyzed using one-way analysis of variance. For all statistical tests, the a value was 0.05.
Results
We measured the extent of N-glycosylation of the NMDA receptor subunits NR1, NR2A, NR2B, and NR2C, and the KA receptor subunits GluR6 and KA2, in DLPFC of schizophrenia patients and a comparison group. Samples were incubated with glycosidases that differed in their specificity toward N-linked glycans: Endo H removes immature high mannose-containing and hybrid sugars, whereas PNGase F removes all N-linked sugars leading to total N-linked deglycosylation. The removal of sugars is inferred by a decrease in the molecular mass.
All the subunits studied, except NR2C, were sensitive to enzymatic deglycosylation (Fig. 1) , reflected by measurable changes in the electrophoretic mobility of each subunit after enzymatic treatment. We assayed the NR1 subunit after Endo H treatment only because NR1 immunoreactivity was undetectable in samples incubated in the PNGase F-specific buffer. Of all subunits studied, only GluR6 was significantly more sensitive to Endo H-mediated deglycosylation in schizophrenia patients than in the comparison participants (12.4±1.3 vs. 11.5±1.0 kDa, P < 0.05). We compared expression levels of GluR6 protein normalized to b-tubulin and did not find any significant difference between schizophrenia patients (0.7±0.4) and comparison participants (0.9±0.4). We did not observe any differences in molecular mass shifts for the other subunits between schizophrenia patients and comparison participants after either Endo H or PNGase F treatment (Table 1) .
Discussion
Previously, we have found that proteins associated with glutamate neurotransmission are abnormally N-glycosylated in schizophrenia, including the GluR2 subunit of the AMPA receptor [9, 12] . In this work, we have extended the characterization of N-glycosylation in schizophrenia to subunits of the other families of iGluRs, NMDA and KA receptors. We found that the GluR6 KA receptor subunit is abnormally N-glycosylated in schizophrenia. We also found the N-glycosylation status of NR1, NR2A, NR2B, NR2C, and KA2; all analyzed subunits, except NR2C, were sensitive to Endo H or PNGase F treatment, but no significant changes were found between schizophrenia patients and comparison participants for those subunits.
GluR6 was significantly more sensitive to Endo H-mediated deglycosylation in schizophrenia, suggesting that either a larger fraction of this subunit contains N-linked high mannose and/or hybrid sugars or that sugars attached to GluR6 have a larger molecular weight in schizophrenia patients than in comparison participants. This is intriguing as all of our previous findings of N-glycosylation abnormalities of proteins associated with glutamatergic neurotransmission in schizophrenia have been of decreased N-glycans on these proteins [9, 12] . Endo H recognizes and removes only glycans that are specific to proteins residing in the proximal secretory pathway (ER to medial-Golgi) [14, 15] , suggesting that in schizophrenia, a larger fraction of the GluR6 subunit may be retained in the ER or Golgi apparatus, limiting the amount of GluR6 that can be assembled into active KA receptors. Given our previous finding of decreased ER content of the NR2B NMDA receptor subunit [11] , it is surprising that we did not find any changes in Nglycosylation of this or other NMDA receptor subunits. These data taken together, however, are consistent with abnormal trafficking of ionotropic receptors in schizophrenia, but the mechanism of this dysregulation is likely multifactorial.
Abnormalities of N-glycosylation and forward trafficking of GluR6 may have functional consequences in schizophrenia. GluR6 is the major subunit of KA receptors and it regulates KA receptor function. Most KA receptors contain the GluR6 subunit, and the cell-surface expression of KA receptors containing this subunit or other subunits/their splice variants is regulated by GluR6 [16, 17] . Unlike NMDA or AMPA receptors, KA receptors are found on both sides of the synapse and play a major role in neurotransmitter release, neuronal excitability, and plasticity [18] [19] [20] . They can act as iGluRs, but also regulate metabotropic neuronal signaling pathways [21] . GluR6-containing KA receptors have been shown to be important in the generation of brain oscillatory activity [22] . The expression of a nonfunctional GluR6 subunit has been proposed to disrupt development and lead to cognitive dysfunction [23, 24] .
Conclusion
We found altered N-glycosylation of the GluR6 KA receptor subunit, which may result in attenuation of KA receptor function, thus affecting glutamate neurotransmission, and in turn contributing to the glutamatergic and cognitive dysfunction in schizophrenia. This finding, together with our previous findings, suggests that abnormal trafficking and/or recycling of glutamate receptors and transporters may contribute toward the mechanism underlying dysfunctional glutamate neurotransmission in this disorder. It remains to be determined how potentially dysfunctional KA receptors contribute toward the pathogenesis or the pathophysiology of schizophrenia, but given their modulatory roles, they may be involved in disturbances in excitatory neurotransmission associated with this disorder.
